+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to compare the safety and effectiveness of two types of multifocal contact lenses, ACUVUE4 OASYS MAX 1-Day Multifocal and DAILIES4 AquaComfort Plus4 Multifocal. The study is designed as a randomized, single-masked clinical trial with two parallel groups to evaluate visual acuity and ocular safety in adults aged 40 to 70 years. Participants will be monitored for both near and distance vision performance as well as any lens-related eye events. Participants will be randomly assigned to wear either the Senofilcon A lens ACUVUE4 OASYS MAX 1-Day Multifocal or the Nelfilcon A lens DAILIES4 AquaComfort Plus4 Multifocal for the duration of the study. The study consists of four visits where the lenses performance is assessed at one week and one month after initial fitting. Both lenses are soft multifocal contact lenses designed to correct presbyopia and improve visual acuity at various distances. During the study, participants will undergo evaluations of binocular visual acuity at distance, intermediate, and near ranges, along with monitoring for ocular adverse events and slit lamp findings. The primary outcomes measured include visual acuity at one week and the incidence of lens-related eye issues up to one month. This study requires participants to attend four visits over the course of the study period, which lasts approximately one month after lens fitting.

Age: 40Years - 70YearsAll GendersPhase Not Applicable
11 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations